Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA; HPTN 083‐02 Study Team. Psaros C, et al. Among authors: rooney j. J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252. J Int AIDS Soc. 2024. PMID: 38783534 Free PMC article.
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project.
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V; Forum for Collaborative Research Recency Assay Working Group. Parkin N, et al. Clin Pharmacol Ther. 2023 Jul;114(1):29-40. doi: 10.1002/cpt.2830. Epub 2023 Jan 5. Clin Pharmacol Ther. 2023. PMID: 36550769 Review.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, McCauley M, Rinehart AR, St Clair M, Ford SL, Rooney JF, Adeyeye A, Chariyalertsak S, Mayer K, Arduino RC, Cohen MS, Grinsztejn B, Hanscom B, Landovitz RJ, Eshleman SH. Marzinke MA, et al. Among authors: rooney jf. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0005323. doi: 10.1128/aac.00053-23. Epub 2023 Mar 30. Antimicrob Agents Chemother. 2023. PMID: 36995219 Free PMC article.
High PrEP uptake, adherence, persistence and effectiveness outcomes among young Thai men and transgender women who sell sex in Bangkok and Pattaya, Thailand: findings from the open-label combination HIV prevention effectiveness (COPE) study.
Weir BW, Wirtz AL, Chemnasiri T, Baral SD, Decker M, Dun C, Hnin Mon SH, Ungsedhapand C, Dunne EF, Woodring J, Pattanasin S, Sukwicha W, Thigpen MC, Varangrat A, Warapornmongkholkul A, O'Connor S, Ngo JP, Qaragholi N, Sisel HI, Truong JM, Janyam S, Linjongrat D, Sriplienchan S, Sirivongrangson P, Rooney JF, Sullivan P, Chua-Intra B, Hickey AC, Beyrer C; COPE Study Teamabcdefghijklmn; COPE Study Team. Weir BW, et al. Among authors: rooney jf. Lancet Reg Health Southeast Asia. 2023 May 25;15:100217. doi: 10.1016/j.lansea.2023.100217. eCollection 2023 Aug. Lancet Reg Health Southeast Asia. 2023. PMID: 37614346 Free PMC article.
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Marzinke MA, Hanscom B, Wang Z, Safren SA, Psaros C, Donnell D, Richardson PA, Sullivan P, Eshleman SH, Jennings A, Feliciano KG, Jalil E, Coutinho C, Cardozo N, Maia B, Khan T, Singh Y, Middelkoop K, Franks J, Valencia J, Sanchez N, Lucas J, Rooney JF, Rinehart AR, Ford S, Adeyeye A, Cohen MS, McCauley M, Landovitz RJ, Grinsztejn B; HPTN 083 study group. Marzinke MA, et al. Among authors: rooney jf. Lancet HIV. 2023 Nov;10(11):e703-e712. doi: 10.1016/S2352-3018(23)00200-X. Epub 2023 Sep 29. Lancet HIV. 2023. PMID: 37783219 Free PMC article. Clinical Trial.
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, Macdonald P, Milan G, Palanee-Phillips T, Reddy K, Tahuringana E, Muhlanga F, Nakabiito C, Bekker LG, Siziba B, Hillier SL, Baeten JM, Garcia M, Johnson S, McClure T, Levy L, Livant E, Jacobson C, Soto-Torres L, van der Straten A, Hosek S, Rooney JF, Steytler J, Bunge K, Parikh U, Hendrix C, Anderson P, Ngure K; REACH Protocol Team. Nair G, et al. Among authors: rooney jf. Lancet HIV. 2023 Dec;10(12):e779-e789. doi: 10.1016/S2352-3018(23)00227-8. Epub 2023 Oct 25. Lancet HIV. 2023. PMID: 37898146 Clinical Trial.
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B; HPTN 083 Study Team. Landovitz RJ, et al. Among authors: rooney jf. Lancet HIV. 2023 Dec;10(12):e767-e778. doi: 10.1016/S2352-3018(23)00261-8. Epub 2023 Nov 9. Lancet HIV. 2023. PMID: 37952550 Free PMC article. Clinical Trial.
Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis.
Fogel JM, Piwowar-Manning E, Moser A, Hill T, Ahmed S, Cummings V, Mostafa HH, Wang Z, Jennings A, Gallardo-Cartagena JA, Figueroa MI, St Clair M, Rinehart AR, Adeyeye A, Rooney JF, Cohen MS, Grinsztejn B, Landovitz RJ, Eshleman SH; HPTN 083 Study Team. Fogel JM, et al. Among authors: rooney jf. Microbiol Spectr. 2024 Jul 9;12(8):e0030724. doi: 10.1128/spectrum.00307-24. Online ahead of print. Microbiol Spectr. 2024. PMID: 38980027 Free PMC article.
Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
Marzinke MA, Han K, Hanscom B, Guo X, Piwowar-Manning E, Hendrix CW, Rose S, Spooner E, Mathew C, Innes S, Sekabira R, Mutambanengwe M, Rooney JF, Rinehart AR, Adeyeye A, Cohen MS, Hosseinipour M, Ford SL, Delany-Moretlwe S. Marzinke MA, et al. Among authors: rooney jf. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0099424. doi: 10.1128/aac.00994-24. Epub 2024 Sep 23. Antimicrob Agents Chemother. 2024. PMID: 39311597 Clinical Trial.
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084.
Fogel JM, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke MA, Wang Z, Guo X, McCauley M, Farrior J, Tran HV, Ungsedhapand C, Mathew CA, Mpendo J, Rinehart AR, Rooney JF, Cohen MS, Hanscom B, Grinsztejn B, Hosseinipour MC, Delany-Moretlwe S, Landovitz RJ, Eshleman SH; HPTN 083 and HPTN 084 Study Teams. Fogel JM, et al. Among authors: rooney jf. AIDS Res Hum Retroviruses. 2024 Oct 28. doi: 10.1089/aid.2024.0049. Online ahead of print. AIDS Res Hum Retroviruses. 2024. PMID: 39466048
643 results